Clinical Trials Arena on MSN3d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...
BioSpace2d
Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
PMLive1d
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
Fierce Biotech3d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Pharmabiz2d
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Fox 5 San Diego5d
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE ...
Yahoo Finance5d
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...